Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) Peptid
PARK2
Reaktivität: Säugetier
Wirt: Synthetic
BP, WB, IHC
-
- Target Alle Parkin (PARK2) Produkte
- Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))
- Protein-Typ
- Synthetic
- Spezies
- Säugetier
-
Quelle
- Synthetic
- Applikation
- Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
- Sequenz
- YTRYQQYGAE ECVLQMGGVL CPRPGCGAGL LPEQGQRKVT CEGGNGLGCG
- Produktmerkmale
-
A synthetic peptide for use as a blocking control in assays to test for specificity of Park2 antibody,
Alternative Names: Park2 control peptide, Park2 antibody Blocking Peptide, Anti-Park2 Blocking Peptide, Parkinson disease, autosomal recessive, juvenile 2, parkin Blocking Peptide, MGC130518 Blocking Peptide, PRKN Blocking Peptide, Park2, Park-2, Park 2, Park-2 Blocking Peptide, Park 2 Blocking Peptide - Aufreinigung
- Serum
-
-
- Applikationshinweise
- Optimal conditions should be determined by the investigator
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
- Buffer
- PBS
- Handhabung
- Avoid repeated freeze/thaw cycles.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Store at -20 °C long term.
-
- Target
- Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))
- Hintergrund
- Park2 functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5 and AIMP2. Park2 may play a more general role in the ubiquitin proteasomal pathway by participating in the removal and/or detoxification of abnormally folded or damaged protein. Park2 limits the production of reactive oxygen species (ROS).
- Molekulargewicht
- 51 kDa
-
Sie sind hier:
